And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown to give rapid relief to depression symptoms, was just approved as a stand-alone therapy by the Food and ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ... Spravato administered as a nasal spray achieved a rapid and ...

A report from the Department of Homeland Security about a man whose case has received national attention after he was deported from Maryland to El Salvador alleged that he was pulled over by the ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

Emergency crews were called to the scene after a semi crashed into a building in West Chicago on Wednesday afternoon. A federal judge is expected to rule on a request to stop President Trump's ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...

Johnson & Johnson has priced its new ... 25% and 52% cheaper to meet its value threshold. The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY ... Learn more about this approval in Johnson ...